AR072279A1 - Derivados de isoquinolina e isoquinolinona bi- y policiclicos sustituidos, uso del compuesto para producir un medicamento, y un medicamento en base al compuesto - Google Patents

Derivados de isoquinolina e isoquinolinona bi- y policiclicos sustituidos, uso del compuesto para producir un medicamento, y un medicamento en base al compuesto

Info

Publication number
AR072279A1
AR072279A1 ARP090102283A ARP090102283A AR072279A1 AR 072279 A1 AR072279 A1 AR 072279A1 AR P090102283 A ARP090102283 A AR P090102283A AR P090102283 A ARP090102283 A AR P090102283A AR 072279 A1 AR072279 A1 AR 072279A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
aryl
heterocycloalkyl
cycloalkyl
Prior art date
Application number
ARP090102283A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR072279A1 publication Critical patent/AR072279A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)

Abstract

Estos compuestos son utiles para el tratamiento y/o prevencion de enfermedades asociadas con Rho-quinasa y/o la fosforilacion mediada por Rho-quinasa, tales como enfermedades cardiovasculares, hipertension pulmonar y ocular, enfermedad coronaria, nefropatías, degeneracion neuronal, COPD y enfermedades autoinmunes. Reivindicacion 1: Un compuesto de la formula (1) en donde R1 es H, OH o NH2; R3 es H, halogeno, CN, alquilo C1-6, OH, NH2 o NHR'; R4 es H, halogeno, hidroxi, CN, alquilo C1-6, R' o alquilen C1-6-R'; R5 es H, halogeno, CN, alquilo C1-6, o R'; R7 es H, halogeno, CN, alquilo C1-6, O-alquilo C1-6, R' o SO2-NH2; R8 es H, halogeno o alquilo C1-6; R6 es un alquileno C1-4 unido al anillo de cicloalquilo, en el que el alquileno C1-4 forma un segundo enlace a un átomo de carbono diferente del anillo de cicloalquilo para formar un sistema de anillo bicíclico, en donde en el sistema de anillo bicíclico uno o dos átomos de carbono están reemplazados por un grupo independientemente seleccionado de O, N-R13, S, SO o SO2 o, si m y s son 2, m es 3 y s es 1, o m es 4 y s es 0, R6 es CH2-CH-(CH2)2, el cual está unido con un CH2 al anillo de cicloalquilo y los otros dos CH2 están unidos a diferentes átomos de carbono del anillo de cicloalquilo, y, si m es 3 y s es 3, R6 son dos grupos metileno unidos a diferentes átomos de carbono del anillo de cicloalquilo, en donde los grupos metileno del grupo CH2-CH-(CH2)2 están unidos a átomos de carbono del anillo de cicloalquilo y forman un sistema de adamantano de la formula (2) en donde L puede estar unido a cualquier átomo de carbono secundario o terciario, o R6, junto con R11 y el átomo de N forman un heterocicloalquilo C3-8 que está conectado en forma de un sistema de anillo espirocíclico para formar un residuo de la formula (3) en donde el sistema de anillo bicíclico o el sistema de adamantano o el sistema de anillo que contiene heterocicloalquilo C3-8 no está sustituido o está opcionalmente sustituido con R9; R9 es R', OH, halogeno, alquilo C1-6, O-alquilo C1-6, alquileno C1-6-R', alquenilo C2-6, alquinilo C2-6, alquileno C1-6-O-R', alquileno C1-6-CH[R']2, alquileno C1-6-C(O)-R', alquileno C1-6-C(O)NH2, alquileno C1-6-C(O)NH-R', alquileno C1-6-C(O)NH-alquilo C1-6, alquileno C1-6-C(O)N[alquilo C1-6]2, alquileno C1-6-C(O)N[R']2, alquileno C1-6-C(O)O-alquilo C1-6, COOH, C(O)O-alquilo C1-6, C(O)OR', C(O)-alquilo C1-6, C(O)R', CONH2, C(O)-NH-alquenilo C2-6, C(O)-NH-alquinilo C2-6, C(O)NH-alquilo C1-6, C(O)NHR', C(O)-NH-alquileno C1-6-R', C(O)N[alquilo C1-6]R', C(O)N[alquilo C1-6]2, C(O)-alquileno C1-6-R', o C(O)O-alquileno C1-6-R'; R11 y R12 son, independientemente entre sí, H, R', alquilo C1-6; alquilen C1-6-R', alquilen C1-6-O-alquilo C1-6, alquilen C1-6-O-R', alquilen C1-6-CH[R']2, alquilen C1-6-C(O)-R', alquilen C1-6-C(O)NH2, alquilen C1-6-C(O)NH-R', alquilen C1-6-C(O)NH-alquilo C1-6, alquilen C1-6-C(O)N[alquilo C1-6]2, alquilen C1-6-C(O)N[R']2, alquilen C1-6-C(O)O-alquilo C1-6, C(O)O-alquilo C1-6, C(O)OR', C(O)-alquilo C1-6, C(O)R', C(O)NH-alquilo C1-6, C(O)NHR', C(O)N[alquilo C1-6]R', C(O)N[alquilo C1-6]2, C(O)-alquilen C1-6-R', C(O)O-alquilen C1-6-R'; o R11 y R12, junto con el átomo de N al que están unidos, forman un grupo heterocicloalquilo C3-8; R13 es H o alquilo C1-6; n es 0, 1, 2, 3 o 4; m es 1, 2, 3 o 4; s es 0, 1, 2 o 3; L es O(CH2)p, S(CH2)p, S(O)(CH2)p, SO2(CH2)p, NH(CH2)p, N-alquil C1-6-(CH2)p, N-cicloalquil C3-6-(CH2)p; o N[alquileno C1-3-R']-(CH2)p; p es 0, 1, 2, 3 o 4; R' es cicloalquilo C3-8, heteroarilo C5-10, heterocicloalquilo C3-8, arilo C6-10; en donde en los restos R3 a R13 alquilo o alquileno está no sustituido o está opcionalmente sustituido una o más veces con OH, OCH3, C(O)OH, C(O)OCH3, NH2, NHCH3, N(CH3)2, C(O)NH2, C(O)NHCH3 o C(O)N(CH3)2; en donde en los restos R3 a R13 cicloalquilo o heterocicloalquilo está no sustituido o está opcionalmente sustituido una o más veces con alquilo C1-6, halogeno, OH, OCH3, C(O)OH, C(O)OCH3, NH2, NHCH3, N(CH3)2, C(O)NH2, C(O)NHCH3 o C(O)N(CH3)2, en donde en los restos R3 a R13 alquilo o alquileno no está sustituido o está opcionalmente sustituido una o más veces con halogeno; en donde en los restos R3 a R13 arilo C6-10 y heteroarilo C5-10 están no sustituidos o están opcionalmente sustituidos, una o más veces, con un grupo independientemente seleccionado de halogeno, OH, NO2, N3, CN, C(O)-alquilo C1-6, C(O)-arilo C6-10, C(O)OH, C(O)Oalquilo C1-6, C(O)NH2, C(O)NHalquilo C1-6, C(O)N[alquilo C1-6]2, cicloalquilo C3-8, alquilo C1-6, alquileno C1-6-NHalquilo C1-6, alquileno C1-6-N[alquilo C1-6]2, alquenilo C2-6, alquinilo C2-6, O-alquilo C1-6, O-C(O)-alquilo C1-6, PO3H2, SO3H, SO2-NH2, SO2NHalquilo C1-6, SO2N[alquilo C1-6]2, S-alquilo C1-6; SO-alquilo C1-6, SO2-alquilo C1-6, SO2-N=CH-N[alquilo C1-6]2, SF5, C(NH)(NH2), NH2, NH-alquilo C1-6, N[alquilo C1-6]2, NH-C(O)-alquilo C1-6, NH-C(O)O-alquilo C1-6, NH-SO2-alquilo C1-6, NH-SO2-arilo C6-10, NH-SO2-heteroarilo C5-10, NH-SO2-heterocicloalquilo C3-8, Nalquilo C1-6-C(O)-alquilo C1-6, Nalquilo C1-6-C(O)O-alquilo C1-6, Nalquilo C1-6-C(O)-NH-alquilo C1-6, arilo C6-10, alquileno C1-6-arilo C6-10, O-arilo C6-10, O-alquileno C1-6-arilo C6-10, heteroarilo C5-10, heterocicloalquilo C3-8, alquileno C1-6-heteroarilo C5-10, alquileno C1-6-heterocicloalquilo C3-8, O-alquileno C1-6-heteroarilo C5-10, O-alquileno C1-6-heterocicloalquilo C3-8, en donde dicho arilo C6-10, heteroarilo C5-10, heterocicloalquilo C3-8 o cicloalquilo C3-8 puede estar sustituido, una a tres veces, con un grupo, independientemente seleccionado de halogeno, OH, NO2, CN, O-alquilo C1-6, alquilo C1-6, NH2, NHalquilo C1-6, N[alquilo C1-6]2, SO2CH3, C(O)OH, C(O)O-alquilo C1-6, C(O)NH2, alquileno C1-6-O-alquilo C1-6, alquileno C1-6-O-arilo C6-10 u O-alquileno C1-6-arilo C6-10; o en los que arilo C6-10 está sustituido vecinalmente con un grupo O-alquilen C1-4-O, con lo que se forma, junto con los átomos de carbono a los que están unidos los átomos de oxígeno, un anillo de 5-8 miembros; y en donde los sustituyentes arilo de grupos arilo C6-10, heteroarilo C5-10, heterocicloalquilo C3-8 y cicloalquilo C3-8 pueden no estar adicionalmente sustituidos con un grupo que contiene arilo, heteroarilo, heterocicloalquilo o cicloalquilo; sus formas estereoisoméricas y/o tautoméricas y/o sus sales farmacéuticamente aceptables.
ARP090102283A 2008-06-24 2009-06-22 Derivados de isoquinolina e isoquinolinona bi- y policiclicos sustituidos, uso del compuesto para producir un medicamento, y un medicamento en base al compuesto AR072279A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290607 2008-06-24

Publications (1)

Publication Number Publication Date
AR072279A1 true AR072279A1 (es) 2010-08-18

Family

ID=40076742

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102283A AR072279A1 (es) 2008-06-24 2009-06-22 Derivados de isoquinolina e isoquinolinona bi- y policiclicos sustituidos, uso del compuesto para producir un medicamento, y un medicamento en base al compuesto

Country Status (27)

Country Link
US (1) US8524737B2 (es)
EP (1) EP2303845B1 (es)
JP (1) JP5715561B2 (es)
KR (1) KR101692211B1 (es)
CN (1) CN102076667B (es)
AR (1) AR072279A1 (es)
AU (1) AU2009262509B2 (es)
BR (1) BRPI0914330A2 (es)
CA (1) CA2728123C (es)
CO (1) CO6321251A2 (es)
DK (1) DK2303845T3 (es)
ES (1) ES2434121T3 (es)
HK (1) HK1152308A1 (es)
HR (1) HRP20131040T1 (es)
IL (1) IL210114A (es)
MA (1) MA32401B1 (es)
MX (1) MX2010013867A (es)
MY (1) MY153756A (es)
NZ (1) NZ590067A (es)
PL (1) PL2303845T3 (es)
PT (1) PT2303845E (es)
RU (1) RU2532481C2 (es)
SI (1) SI2303845T1 (es)
TW (1) TWI466868B (es)
UY (1) UY31924A (es)
WO (1) WO2009156092A2 (es)
ZA (1) ZA201008120B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2702600A1 (de) * 1977-01-22 1978-07-27 Thomae Gmbh Dr K Neue aminoalkoxyphenyl-derivate
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
EP0541559A1 (en) 1990-07-31 1993-05-19 E.I. Du Pont De Nemours And Company Catalytic equilibration of selected halocarbons
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
AU738620B2 (en) 1996-08-12 2001-09-20 Mitsubishi Pharma Corporation Pharmaceutical agent containing Rho kinase inhibitor
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
WO1999011642A1 (en) 1997-08-29 1999-03-11 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
KR20020080378A (ko) 2000-01-20 2002-10-23 에자이 가부시키가이샤 신규 피페리딘 화합물 및 그의 의약
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001064238A2 (en) 2000-02-29 2001-09-07 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002034712A1 (fr) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Procede de preparation de composes aromatiques substitues et produits intermediaires associes
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
AU2003281623B8 (en) * 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
CA2502583A1 (en) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
WO2004113297A2 (en) 2003-06-24 2004-12-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CN1856475A (zh) 2003-09-23 2006-11-01 默克公司 异喹啉钾通道抑制剂
AU2004276236B2 (en) 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
US20070060595A1 (en) * 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
US20080312189A1 (en) 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
PT1899322E (pt) * 2005-06-28 2009-11-09 Sanofi Aventis Derivados de isoquinolina como inibidores de rho-cinase
EP2385047B1 (en) * 2005-07-26 2013-05-29 Sanofi Piperidinyl-substituted isoquinolone derivatives
EP1912949B1 (en) * 2005-07-26 2011-08-24 Sanofi Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
TW200745101A (en) * 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
CA2664335C (en) * 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
MY150746A (en) * 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
CN101573338B (zh) * 2006-12-27 2013-03-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮和异喹啉酮衍生物
AU2007338412B2 (en) 2006-12-27 2013-03-14 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
DK2132194T3 (da) * 2006-12-27 2011-06-27 Sanofi Aventis Substituerede isoquinoliner og deres anvendelse som Rho-kinase inhibitorer
NZ577980A (en) * 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
WO2008077554A1 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
AU2007338408B2 (en) * 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives

Also Published As

Publication number Publication date
PT2303845E (pt) 2013-11-25
NZ590067A (en) 2012-09-28
IL210114A (en) 2014-07-31
TWI466868B (zh) 2015-01-01
EP2303845B1 (en) 2013-09-18
CN102076667A (zh) 2011-05-25
ES2434121T3 (es) 2013-12-13
AU2009262509A1 (en) 2009-12-30
WO2009156092A3 (en) 2010-04-08
EP2303845A2 (en) 2011-04-06
US8524737B2 (en) 2013-09-03
KR101692211B1 (ko) 2017-01-03
DK2303845T3 (da) 2013-12-16
KR20110026430A (ko) 2011-03-15
IL210114A0 (en) 2011-02-28
WO2009156092A2 (en) 2009-12-30
UY31924A (es) 2010-01-29
ZA201008120B (en) 2011-08-31
HRP20131040T1 (hr) 2013-12-06
CA2728123C (en) 2017-02-21
RU2532481C2 (ru) 2014-11-10
CO6321251A2 (es) 2011-09-20
US20110190340A1 (en) 2011-08-04
PL2303845T3 (pl) 2014-03-31
RU2011102460A (ru) 2012-07-27
JP2011525508A (ja) 2011-09-22
MY153756A (en) 2015-03-13
AU2009262509B2 (en) 2014-01-30
CA2728123A1 (en) 2009-12-30
MX2010013867A (es) 2011-02-24
BRPI0914330A2 (pt) 2019-09-24
HK1152308A1 (en) 2012-02-24
MA32401B1 (fr) 2011-06-01
TW201014825A (en) 2010-04-16
JP5715561B2 (ja) 2015-05-07
SI2303845T1 (sl) 2013-12-31
CN102076667B (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
AR064531A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la rho-quinasa
AR064493A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos
AR072281A1 (es) Isoquinolinas e isoquinolinonas sustituidas
AR064533A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos y su uso en la produccion de un medicamento para el tratamiento de enfermedades relacionadas con la inhibicion de la rho-quinasa.
ES2481409T3 (es) Compuestos 2,5,6,7-tetrahidro-[1,4]oxazepin-3-ilamina o 2,3,6,7-tetrahidro-[1,4]oxazepin-5-ilamina
AR054518A1 (es) Derivados de isoquinolina
AR064492A1 (es) Derivados de isoquinolona sustituidos con cicloalquilamina
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
ES2686501T3 (es) Pirazolo[1,5-a]piridinas sustituidas como inhibidores de la quinasa del receptor de tropomiosina (Trk)
AR034390A1 (es) Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa
BR112012018865A2 (pt) naftiridinas substituídas e seu uso como inibidores de quinase syk
AR036716A1 (es) Un compuesto derivado de bencimidazolidinona, metodos que lo utilizan, una composicion farmaceutica que lo comprende y uso de dicho compuesto o composicion
AR071778A1 (es) Imidazo[1,2-b]piridazinas inhibidores de proteinquinasas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento del cancer, enfermedades oseas y autoinmunes, entre otras.
AR066142A1 (es) IMIDAZOTRIAZINAS E IMIDAZOPIRIMIDINAS COMO INHIBIDORES DE QUINASA, UNA COMPOSICION QUE LAS INCLUYE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LA DESREGULACIoN DE LA VIA DE SENALIZACIoN HGF/C-MET
AR082391A1 (es) Inhibidores biciclicos de acetil-coa y usos de los mismos
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
AR049521A1 (es) Derivados de pirrazol - pirimidina
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
AR056265A1 (es) N-aminometilensulfonamidas sustituidas, su preparacion y su uso como medicamentos
AR064345A1 (es) Derivados de 8-oxoadenina
AR056980A1 (es) Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
CO6251264A2 (es) Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k

Legal Events

Date Code Title Description
FB Suspension of granting procedure